Last checked at 14 Jan 2014 07:00
14 January 2014
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Trading Update and Notice of Results
Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in aluminium free allergy vaccines, will announce its unaudited interim results for the period ended 31 December 2013 on 24 March 2014.
The Company is pleased to report that it expects first half revenues before milestones and rebates of approximately £29.9m (H1 2013: £26.6m), an improvement of 12%. This double digit sales growth has been driven by the Company's improving trading performance as it continues to increase its market share in all of its main markets and supported by a foreign exchange benefit of £1.6m.
-Ends-
For further information
Allergy Therapeutics | +44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director |
|
| |
Peel Hunt LLP | +44 (0) 20 7418 8900 |
James Steel Oliver Jackson |
|
| |
FTI Consulting | +44 (0) 207 831 3113 |
Simon Conway Victoria Foster Mitchell |
|
Notes to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of £39.3 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.
Allergy Therapeutics vaccines are aluminium free, containing instead tyrosine as a depot, Tyrosine is a natural product that is readily metabolised and eliminated from the body.